RhoVac is a pharmaceutical company. Today, the focus is on the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is a significant part of the operations where the body's immune system is used to fight and eliminate cancer cell. The company's drug candidate is used in combination with surgery or radiation therapy. The company was established in 2007 and is based in Lund.

Quotes for RhoVac AB

Right Now

+/-
-0.3
%
-2,04%
Latest
14.38
High
14.6
Low
14.14
Volume
11 642
Turnover (SEK)
166 731
Value (MSEK)
273,9

Board

CEO

  • Anders Månsson

Chairman Of The Board

  • Gunnar Gårdemyr

Board

  • Anders Ljungqvist
  • Cristina Glad
  • Lars Hedbys
  • Lars Höckenström

Videos

Largest Owners

Name Capital % Votes % Date
Rutger Arnhult 20,41 20,41 2020-03-31
Nordic Cross Asset Management 9,22 9,22 2020-06-30
RQ Solutions ApS 7,56 7,56 2020-03-31
Avanza Pension 4,04 4,04 2020-03-31
Göran Källebo 3,34 3,34 2020-03-31
Nordnet Pensionsförsäkring 2,59 2,59 2020-03-31
Gunvald Berger 1,86 1,86 2020-03-31
Anders Bremer 1,31 1,31 2020-03-31
Linfan Zhang 1,25 1,25 2020-03-31
Nils Berntsson 1,18 1,18 2020-03-31
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2020-08-28 Delårsrapport 2020-Q2

  • 2020-11-13 Delårsrapport 2020-Q3